Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemiaGabriela Forestieri, Adalgisa Condoluci, Gaby Fahrni et al.|Hematological Oncology|2022Cited by 2
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinibAdalgisa Condoluci, Luca Ceriani, Lisa Milan et al.|Hematological Oncology|2022Cited by 1
IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIAAdalgisa Condoluci, Davide Rossi, Francesco Passamonti et al.|Hematological Oncology|2021Cited by 0
Author response for "Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia"Gabriela Forestieri, Adalgisa Condoluci, Lodovico Terzi di Bergamo et al.|Unknown|2022Cited by 0
Author response for "Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib"Adalgisa Condoluci, Luca Ceriani, Lisa Milan et al.|Unknown|2022Cited by 0